Knowledge of tumor/blood genomic testing (NGS) and ESR1 mutations in a survey of patients with ER+/HER2-metastatic breast cancer (mBC)

被引：0
|
作者：
Meisel, Jane
Sammons, Sarah L.
Shanahan, Kelly
Pluard, Timothy
Kozlowski, Monica
Carroll, Dominic
Attias, Elizabeth
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 05期
关键词：
D O I：
10.1158/1538-7445.SABCS22-P6-09-02
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P6-09-02
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Time-to-failure in 1st-line endocrine therapy with ER+/HER2-metastatic breast cancer
    Nishimura, S.
    Akiyoshi, S.
    Koga, C.
    Oikawa, M.
    Nskamura, Y.
    Ishida, M.
    Ohno, S.
    BREAST, 2015, 24 : S82 - S83
  • [32] Co-Targeting ER and FGFR in patients with ER+/HER2-FGFR amplified (amp) Metastatic Breast Cancer (MBC)
    Jhaveri, K.
    Syed, U.
    Wong, S.
    D'andrea, G.
    Lake, D.
    Goldfarb, S.
    Gajria, D.
    Ligresti, L.
    Rogado, A.
    Reis-Filho, J.
    Chandarlapaty, S.
    EUROPEAN JOURNAL OF CANCER, 2018, 103 : E42 - E42
  • [33] ABERRANT METHYLATION OF ESR1 IN BLOOD AND ASSOCIATION WITH ESR1 NEGATIVE IN TUMOR OF BREAST CANCER PATIENTS
    Martinez-Galan, J.
    Torres-Torres, B.
    del Moral, R.
    Nunez, M. I.
    Valdivia, J.
    Luque, R.
    Penalver, J.
    Rios, S.
    De Almodovar, M. Ruiz
    Delgado, J. R.
    ANNALS OF ONCOLOGY, 2010, 21 : 52 - 52
  • [34] Prediction of early progression (EP) to CDKIs first line treatment in ER+/HER2-metastatic breast cancer (MBC) using machine learning.
    Manuel Jerez, Jose
    Ribelles, Nuria
    Rodriguez-Brazzarola, Pablo
    Diaz Redondo, Tamara
    Jimenez Rodriguez, Begona
    Sanchez-Munoz, Alfonso
    Marquez, Antonia
    Carabantes, Francisco
    Pajares, Bella
    Villar, Ester
    Bermejo-Perez, Maria-Jose
    Saez Lara, Enrique
    Emilia Dominguez-Recio, Maria
    Godoy, Ana
    Mesa, Hector
    Galvez Carvajal, Laura
    Franco, Leo
    Ruiz, Sofia
    Lopez, Irene
    Alba, Emilio
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [35] The Future of ER+/HER2-Metastatic Breast Cancer Therapy: Beyond PI3K Inhibitors
    Stravodimou, Athina
    Voutsadakis, Ioannis A.
    ANTICANCER RESEARCH, 2020, 40 (09) : 4829 - 4841
  • [36] Treatment patterns and clinical outcomes in ER+/HER2-metastatic breast cancer in German real world settings
    Mitra, D.
    Kurosky, S.
    Kaye, J.
    Harbeck, N.
    EUROPEAN JOURNAL OF CANCER, 2017, 72 : S141 - S141
  • [37] Incidence and outcomes among patients with HR+/HER2-metastatic breast cancer (mBC) with co-occurring ESR1 and PIK3CA mutations detected by ctDNA and treated with alpelisib: A retrospective review
    Dempsey, Naomi
    Chamorro, Yolcar
    Tolman, Dana
    Sandoval-Leon, Ana Cristina
    Drusbosky, Leylah
    Lewis, Courtney
    Ahluwalia, Manmeet Singh
    Mahtani, Reshma L.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [38] Biomarker analysis from a phase I study using gedatolisib plus palbociclib plus hormone therapy in ER+/HER2-metastatic breast cancer (mBC).
    Wesolowski, Robert
    Pathan, Nuzhat
    Zhu, Zhou
    Stringer-Reasor, Erica Michelle
    Han, Hyo S.
    Dees, Elizabeth Claire
    Bardia, Aditya
    Layman, Rachel M.
    Weise, Amy
    Kabos, Peter
    Lu, Janice M.
    Kern, Kenneth Alan
    Pierce, Kristen J.
    Rugo, Hope S.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [39] Comparison of ESR1 Mutations in Tumor Tissue and Matched Plasma Samples from Metastatic Breast Cancer Patients
    Takeshita, Takashi
    Yamamoto, Yutaka
    Yamamoto-Ibusuki, Mutsuko
    Tomiguchi, Mai
    Sueta, Aiko
    Murakami, Keiichi
    Omoto, Yoko
    Iwase, Hirotaka
    TRANSLATIONAL ONCOLOGY, 2017, 10 (05): : 766 - 771
  • [40] Heterogeneity and clinical significance of ESR1 mutations in ER-positive metastatic breast cancer patients receiving fulvestrant
    Jill M. Spoerke
    Steven Gendreau
    Kimberly Walter
    Jiaheng Qiu
    Timothy R. Wilson
    Heidi Savage
    Junko Aimi
    Mika K. Derynck
    Meng Chen
    Iris T. Chan
    Lukas C. Amler
    Garret M. Hampton
    Stephen Johnston
    Ian Krop
    Peter Schmid
    Mark R. Lackner
    Nature Communications, 7
12345